This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stewart, M. Articles by Neil, J. C. Search for Related Content PubMed PubMed Citation Articles by Stewart, M. Articles by Neil, J. C.

Insertional Mutagenesis Reveals Progression Genes and Checkpoints in MYC/Runx2 Lymphomas

Molecular Oncology Laboratory, Institute of Comparative Medicine, University of Glasgow Veterinary School, Glasgow, Scotland, United Kingdom

Requests for reprints: Monica Stewart and James Neil, Molecular Oncology Laboratory, Institute of Comparative Medicine, University of Glasgow Veterinary School, Glasgow G61 1QH, Scotland, United Kingdom. Phone: 44-141-3305608; E-mail: m.stewart{at}vet.gla.ac.uk and Phone: 44-141-3302365; E-mail: j.c.neil{at}vet.gla.ac.uk.

In this study, we have exploited the power of insertional mutagenesis to elucidate tumor progression pathways in mice carrying two oncogenes (MYC/Runx2) that collaborate to drive early lymphoma development. Neonatal infection of these mice with Moloney murine leukemia virus resulted in accelerated tumor onset with associated increases in clonal complexity and lymphoid dissemination. Large-scale analysis of retroviral integration sites in these tumors revealed a profound bias towards a narrow range of target genes, including Jdp2 (Jundm2), D cyclin, and Pim family genes. Remarkably, direct PCR analysis of integration hotspots revealed that every progressing tumor consisted of multiple clones harboring hits at these loci, giving access to large numbers of independent insertion events and uncovering the contrasting mutagenic mechanisms operating at each target gene. Direct PCR analysis showed that high-frequency targeting occurs only in the tumor environment in vivo and is specific for the progression gene set. These results indicate that early lymphomas in MYC/Runx2 mice remain dependent on exogenous growth signals, and that progression can be achieved by constitutive activation of pathways converging on a cell cycle checkpoint that acts as the major rate-limiting step for lymphoma outgrowth. [Cancer Res 2007;67(11):5126–33]

This article has been cited by other articles:

				M. H. Rasmussen, B. Wang, M. Wabl, A. L. Nielsen, and F. S. Pedersen Activation of alternative Jdp2 promoters and functional protein isoforms in T-cell lymphomas by retroviral insertion mutagenesis Nucleic Acids Res., August 1, 2009; 37(14): 4657 - 4671. [Abstract] [Full Text] [PDF]

				K. Nakade, J. Pan, T. Yamasaki, T. Murata, B. Wasylyk, and K. K. Yokoyama JDP2 (Jun Dimerization Protein 2)-deficient Mouse Embryonic Fibroblasts Are Resistant to Replicative Senescence J. Biol. Chem., April 17, 2009; 284(16): 10808 - 10817. [Abstract] [Full Text] [PDF]

				K. Weidenfeld-Baranboim, T. Hasin, I. Darlyuk, R. Heinrich, O. Elhanani, J. Pan, K. K. Yokoyama, and A. Aronheim The ubiquitously expressed bZIP inhibitor, JDP2, suppresses the transcription of its homologue immediate early gene counterpart, ATF3 Nucleic Acids Res., April 1, 2009; 37(7): 2194 - 2203. [Abstract] [Full Text] [PDF]

				N. M. Teplyuk, M. Galindo, V. I. Teplyuk, J. Pratap, D. W. Young, D. Lapointe, A. Javed, J. L. Stein, J. B. Lian, G. S. Stein, et al. Runx2 Regulates G Protein-coupled Signaling Pathways to Control Growth of Osteoblast Progenitors J. Biol. Chem., October 10, 2008; 283(41): 27585 - 27597. [Abstract] [Full Text] [PDF]

				K. Weidenfeld-Baranboim, K. Bitton-Worms, and A. Aronheim TRE-dependent transcription activation by JDP2-CHOP10 association Nucleic Acids Res., June 1, 2008; 36(11): 3608 - 3619. [Abstract] [Full Text] [PDF]